2seventy bio(TSVT) - 2024 Q4 - Annual Results

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results $242 million in U.S. Abecma sales in 2024 Approximately $184 million of cash, cash equivalents and marketable securities as of December 31, 2024 Net cash burn of $9 million in the fourth quarter of 2024; path to quarterly breakeven by the end of 2025 CAMBRIDGE, Mass -- [BUSINESS WIRE] -- February 6, 2025 -- 2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales resul ...